GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Cyclically Adjusted FCF per Share

Emmaus Life Sciences (Emmaus Life Sciences) Cyclically Adjusted FCF per Share : $0.00 (As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Emmaus Life Sciences's adjusted free cash flow per share for the three months ended in Sep. 2023 was $0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 66.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 56.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Emmaus Life Sciences was 66.50% per year. The lowest was -2.00% per year. And the median was 10.20% per year.

As of today (2024-06-09), Emmaus Life Sciences's current stock price is $0.092. Emmaus Life Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 was $0.00. Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF of today is .


Emmaus Life Sciences Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Emmaus Life Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Cyclically Adjusted FCF per Share Chart

Emmaus Life Sciences Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,359.28 -611.94 -367.75 -148.67 -23.04

Emmaus Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.84 -23.04 -19.41 -16.86 -

Competitive Comparison of Emmaus Life Sciences's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF falls into.



Emmaus Life Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emmaus Life Sciences's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/129.8595*129.8595
=0.000

Current CPI (Sep. 2023) = 129.8595.

Emmaus Life Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -11.733 98.326 -15.496
201403 -9.904 99.695 -12.901
201406 -8.226 100.560 -10.623
201409 -8.271 100.428 -10.695
201412 -9.341 99.070 -12.244
201503 -6.471 99.621 -8.435
201506 -4.341 100.684 -5.599
201509 -5.224 100.392 -6.757
201512 -7.153 99.792 -9.308
201603 -8.512 100.470 -11.002
201606 -8.416 101.688 -10.748
201609 -2.972 101.861 -3.789
201612 -2.200 101.863 -2.805
201703 -2.329 102.862 -2.940
201706 -2.584 103.349 -3.247
201709 -2.985 104.136 -3.722
201712 -3.418 104.011 -4.267
201803 -3.201 105.290 -3.948
201806 -2.815 106.317 -3.438
201809 -1.519 106.507 -1.852
201812 -1.386 105.998 -1.698
201903 -1.499 107.251 -1.815
201906 -1.232 108.070 -1.480
201909 0.000 108.329 0.000
201912 0.012 108.420 0.014
202003 0.037 108.902 0.044
202006 -0.072 108.767 -0.086
202009 -0.054 109.815 -0.064
202012 0.039 109.897 0.046
202103 -0.082 111.754 -0.095
202106 0.005 114.631 0.006
202109 0.033 115.734 0.037
202112 0.018 117.630 0.020
202203 -0.096 121.301 -0.103
202206 -0.022 125.017 -0.023
202209 -0.019 125.227 -0.020
202212 0.034 125.222 0.035
202303 -0.026 127.348 -0.027
202306 -0.025 128.729 -0.025
202309 0.000 129.860 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Emmaus Life Sciences  (OTCPK:EMMA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Emmaus Life Sciences Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Executives
Seah H. Lim director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee director, officer: Vice Chairman & COO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara director, 10 percent owner, officer: Chairman and CEO 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi director 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark officer: SVP, Clinical Development 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich officer: CIO & SVP 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood director 956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii officer: Chief Financial Officer 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato director 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran officer: Chief Administrative Officer 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey director 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki officer: Sr. VP Finance 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501